- Sees opportunities for legalized marijuana marketing in Canada, Germany, all of Western Europe and South America
- Armed with $43 million in working capital, it sees advantages for itself in product and financing
- It has a proprietary process in its indoor growing environment to control temperature, humidity and water to produce standardized, pesticide-free cannabis
ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) director Aaron Keay said in an interview with CannabisFN (CFN Media) that besides achieving greater market share in Canada, ABcann Global also sees opportunities for growth and presence in Western Europe, Germany and South America (http://cnw.fm/SvJr1). The company sells in its Canadian domestic market through its subsidiary, ABcann Medicinals, Inc.
“We’re now, hopefully, going to be a global presence,” Keay said in the interview. He lauded new CEO Barry Fishman and cited the important values Fishman will bring to the company. He also said the firm’s organic, standardized and pesticide-free cannabis gives it an advantage in competitive marketing. It is achieved through a proprietary process of control of its indoor growing environment where everything is controlled, from temperature to humidity and watering.
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer